{
    "nct_id": "NCT03006302",
    "official_title": "Phase 2 Study of Epacadostat, Pembrolizumab, and CRS-207, With or Without Cyclophosphamide and GVAX Pancreas Vaccine in Patients With Metastatic Pancreas Cancer",
    "inclusion_criteria": "Inclusion Criteria (abbreviated):\n\n* Documented adenocarcinoma of the pancreas\n* Have disease progression after prior chemotherapy for metastatic pancreas cancer (or adjuvant or neoadjuvant if progression occurred within 6 months of completing this regimen)\n* Presence of at least one measurable lesion\n* Patient acceptance to have a tumor biopsy of an accessible lesion at 2 time points (baseline and on study)\n* ECOG performance status of 0 or 1\n* Life expectancy of greater than 3 months\n* Adequate organ and marrow function defined by study-specified laboratory tests\n\nExclusion Criteria (abbreviated):\n\n* Brain metastases\n* Clinical or radiographic ascites (some trace amount may be allowed)\n* Rapidly progressing disease\n* Live vaccine within 30 days of study treatment (flu vaccine allowed)\n* Surgery within 28 days of study treatment (some exceptions for minor procedures)\n* Use of an investigational agent or device within 28 days of study treatment.\n* Chemotherapy, radiation, or biological cancer therapy within 14 days of study treatment.\n* Prior treatment with anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti PD-L2, or with IDO inhibitor.\n* Use of growth factors within 14 days of study treatment\n* Use of any systemic steroids within 14 days of study treatment or other immunosuppressive agents within 7 days of study treatment.\n* Use of more than 2 g/day of acetaminophen\n* Use of any UGT1A9 inhibitor\n* Use of warfarin\n* Use of MAOIs or drugs with significant MAOI activity within the 21 days of screening\n* History of Seratonin Syndome\n* Known allergy to both penicillin and sulfa\n* Known or suspected hypersensitivity to any monoclonal antibody or any study drug component\n* Have artificial joints or implants that cannot be easily removed or a history of infection associated with an implant\n* Significant or malignant pleural effusion\n* New pulmonary embolism, extremity deep venous thromboembolism, or portal vein thrombosis within 2 months of study enrollment\n* History of autoimmune disease (exceptions for Graves or Hashimoto's disease, vitiligo, and type I diabetes mellitus)\n* Gastrointestinal condition that may affect drug absorption\n* Significant heart disease or heart disease requiring antibiotic for prevention of endocarditis\n* History of abnormal electrocardiogram (ECG) that is deemed meaningful by the investigator\n* History of (non-infectious) pneumonitis that required steroids, evidence of interstitial lung disease or active, non-infectious pneumonitis\n* Pulse oximetry of < 92% on room air or the need for supplemental home oxygen\n* Infection with HIV, hepatitis B or hepatitis C\n* Other conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access that would affect the patient's ability to comply with study visits and procedures\n* Pregnant or breastfeeding women\n* Unwillingness or inability to follow the study schedule for any reason\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}